Inhalative IL-10 treatment after bilateral femoral fractures affect pulmonary inflammation in mice

Annals of Anatomy

Volumn 200, Issue , 2015, Pages 73-78

  Lichte, Philipp ^a   Pfeifer, Roman ^a   Kobbe, Philipp ^b   Tohidnezhad, Mersedeh ^b   Pufe, Thomas ^b   Almahmoud, Khalid ^a,c   Hildebrand, Frank ^a,b   Pape, Hans Christoph ^b  

^a Harald Tscherne Lab for Orthopaedic Trauma   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Fracture; Inflammation; Inhalative IL 10; Mouse model

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; RECOMBINANT INTERLEUKIN 10; IL10 PROTEIN, MOUSE; INTERLEUKIN 10; PEROXIDASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMUR FRACTURE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; BIOSYNTHESIS; BONE NAIL; C57BL MOUSE; CHEMICALLY INDUCED; FEMORAL FRACTURES; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; PATHOLOGY;

ANIMALIA; MUS;

ADMINISTRATION, INHALATION; ANIMALS; BONE NAILS; CHEMOKINE CCL2; FEMORAL FRACTURES; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; INTERLEUKIN-6; LUNG; MALE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; PEROXIDASE; PNEUMONIA; RECOMBINANT PROTEINS;

EID: 84991281788     PISSN: 09409602     EISSN: 16180402     Source Type: Journal    
DOI: 10.1016/j.aanat.2015.02.005     Document Type: Article

References (37)

1. Asadullah K., et al. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 2003, 55(2):241-269.
2. Beck-Schimmer B., et al. Pulmonary aspiration: new therapeutic approaches in the experimental model. Anesthesiology 2005, 103(3):556-566.
3. Bivas-Benita M., et al. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005, 61(3):214-218.
4. Donnelly S.C., et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann. Intern. Med. 1996, 125(3):191-196.
5. Ferrer T.J., et al. Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS). J. Surg. Res. 1998, 77(2):157-164.
6. Fiorentino D.F., et al. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147(11):3815-3822.
7. Gong M.N., et al. Interleukin-10 polymorphism in position-1082 and acute respiratory distress syndrome. Eur. Respir. J. 2006, 27(4):674-681.
8. Hess P.J., et al. Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. J. Vasc. Surg. 1997, 26(1):113-118.
9. Hildebrand F., et al. Animal models to assess the local and systemic effects of nailing: review of the literature and considerations for future studies. J. Trauma Acute Care Surg. 2014, 76(6):1495-1506.
10. Hildebrand F., et al. Role of adhesion molecule ICAM in the pathogenesis of polymicrobial sepsis. Exp. Toxicol. Pathol. 2005, 56(4-5):281-290.
11. Inoue G. Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury. J. Infect. Chemother. 2000, 6(1):51-60.
12. Keel M., et al. Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997, 90(9):3356-3363.
13. Khadaroo R.G., et al. Impaired induction of IL-10 expression in the lung following hemorrhagic shock. Shock 2004, 22(4):333-339.
14. Kobayashi H., et al. Susceptibility of thermally injured mice to cytomegalovirus infection. Burns 2001, 27(7):675-680.
15. Kobbe P., et al. Local exposure of bone components to injured soft tissue induces Toll-like receptor 4-dependent systemic inflammation with acute lung injury. Shock 2008, 30(6):686-691.
16. Kobbe P., et al. Inhalative IL-10 attenuates pulmonary inflammation following hemorrhagic shock without major alterations of the systemic inflammatory response. Mediators Inflamm. 2012, 2012:512974.
17. Kobbe P., et al. Increased morbidity and mortality after bilateral femoral shaft fractures: myth or reality in the era of damage control?. Injury 2013, 44(2):221-225.
18. Kobbe P., et al. IL-10 administration attenuates pulmonary neutrophil infiltration and alters pulmonary iNOS activation following hemorrhagic shock. Inflamm. Res. 2009, 58(3):170-174.
19. Kobbe P., et al. Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture. Shock 2008, 30(1):43-47.
20. Koning G.A., et al. Endothelial cells at inflammatory sites as target for therapeutic intervention. Endothelium 2002, 9(3):161-171.
21. Kontakis G.M., et al. Fat embolism: special situations bilateral femoral fractures and pathologic femoral fractures. Injury 2006, 37(Suppl. 4):S19L 24.
22. Krakauer T. IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells. Immunol. Lett. 1995, 45(1-2):61-65.
23. Lichte P., et al. Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. Eur. J. Med. Res. 2014, 19:27.
24. Malleo G., et al. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Cytokine 2008, 41(2):136-143.
25. Menzel C.L., et al. Models of lower extremity damage in mice: time course of organ damage and immune response. J. Surg. Res. 2011, 166(2):e149-e156.
26. Mulligan M.S., et al. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J. Immunol. 1993, 151(10):5666-5674.
27. Opal S.M., DePalo V.A. Anti-inflammatory cytokines. Chest 2000, 117(4):1162-1172.
28. Pfeifer R., et al. Inhalative vs. systemic IL-10 administration: differences in the systemic inflammatory response and end-organ inflammation following hemorrhagic shock. Cytokine 2012, 60(1):266-270.
29. Schindelin J., et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 2012, 9(7):676-682.
30. Schmutzhard J., et al. Murine cerebral malaria: histopathology and ICAM 1 immunohistochemistry of the inner ear. Trop. Med. Int. Health 2011, 16(8):914-922.
31. Schwacha M.G., et al. Resistance of macrophages to the suppressive effect of interleukin-10 following thermal injury. Am. J. Physiol. Cell Physiol. 2001, 281(4):C1180-C1187.
32. Seekamp A., et al. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. J. Trauma 1998, 44(5):874-882.
33. Segel G.B., et al. The paradox of the neutrophil's role in tissue injury. J. Leukoc. Biol. 2011, 89(3):359-372.
34. Song G.Y., et al. What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant?. Surgery 1999, 126(2):378-383.
35. Strecker W., et al. Early biochemical characterization of soft-tissue trauma and fracture trauma. J. Trauma 1999, 47(2):358-364.
36. van Griensven M., et al. Leukocyte-endothelial interactions via ICAM-1 are detrimental in polymicrobial sepsis. Shock 2006, 25(3):254-259.
37. Welborn M.B., et al. Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion. Shock 2003, 20(1):35-40.